A questionnaire-based survey among Indian dermatologists regarding the management of androgenetic alopecia with a novel formulation containing alcohol-free minoxidil, procapil and finasteride
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20254119Keywords:
Androgenetic alopecia, Minoxidil, Adherence, Finasteride, Procapil, EfficacyAbstract
Background: Androgenetic alopecia (AGA) is a common condition affecting all age groups. Topical minoxidil and finasteride are approved treatments for AGA. The study assessed dermatologists’ perceptions of AGA prevalence and opinions regarding minoxidil including combinations, dihydrotestosterone (DHT) blockers and peptides in AGA management.
Methods: The survey was conducted among 245 dermatologists across India, with experience in AGA management. It comprised 32 questions on patient demographics of AGA, treatment strategies and patient compliance with topical minoxidil. Responses from participating dermatologists were analysed and reported using descriptive statistics.
Results: According to 51.4% of dermatologists, AGA prevalence ranged from 30%-40%. Topical minoxidil + finasteride solution with oral nutritional supplements was preferred by 49.3% of dermatologists for treating AGA in men. Around 50.6% dermatologists preferred 5% minoxidil topical solution for treating female patients. About 79.4% agreed or strongly agreed that topical, alcohol-free minoxidil would be better than topical, alcohol-based minoxidil for AGA. According to 51.0% of dermatologists, AGA can be managed more effectively and safely with topical, alcohol-free minoxidil + procapil + finasteride than with topical alcohol-based minoxidil + finasteride. Approximately 55% and 45% of dermatologists rated alcohol-free minoxidil + procapil + finasteride as ‘good’ and ‘excellent’ for treating AGA, respectively. Alcohol-free minoxidil + procapil + finasteride was better tolerated than conventional alcohol-based minoxidil + finasteride by ~62.0% of dermatologists. Patient adherence to alcohol-free minoxidil + procapil + finasteride was rated as ‘good’ by ~64.0% of dermatologists.
Conclusions: Dermatologists preferred alcohol-free minoxidil with procapil and finasteride over conventional alcohol-based formulations in AGA management.
Metrics
References
Mysore V, Parthasaradhi A, Kharkar RD, Ghoshal AK, Ganjoo A, Ravichandran G, et al. Expert consensus on the management of androgenetic alopecia in India. Int J Trichol. 2019;11(3):101-6. DOI: https://doi.org/10.4103/ijt.ijt_24_19
Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: An update. Indian J Dermatol Venereol Leprol. 2013;79(5):613-25. DOI: https://doi.org/10.4103/0378-6323.116730
Kiaee G, Javar HA, Kiaee B, Kiaei S. Preparation and characterization of liposome containing minoxidil and rosemary essential oil. J In Silico In Vitro Pharmacol. 2016;2(3):1-4. DOI: https://doi.org/10.21767/2469-6692.100010
Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186-94. DOI: https://doi.org/10.1111/j.1365-2133.2004.05785.x
Lopedota A, Cutrignelli A, Denora N, Laquintana V, Lopalco A, Selva S, et al. New ethanol and propylene glycol free gel formulations containing a minoxidil-methyl-β-cyclodextrin complex as promising tools for alopecia treatment. Drug Dev Ind Pharm. 2015;41(5):728-36. DOI: https://doi.org/10.3109/03639045.2014.900078
Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol. 2002;46(2):309-12.
Datta D, Saha A, Gharami RC, Das NK, Bandyopadhyay D. Effectiveness of topical minoxidil (5%) plus topical finasteride (0.1%) fixed-dose combination versus topical minoxidil (5%) plus oral finasteride (1 mg/day) in grade II-IV androgenetic alopecia: A randomized, double blind clinical trial. Asian J Res Dermatolog Sci. 2021;4(1):6-18.
Mas-Chamberlin C, Mondon P, Lamy F, Peschard O, Lintner K, France S. Reduction of hair-loss: matrikines and plant molecules to the rescue. In Proceedings of the 7th scientific conference of the Asian society of cosmetic chemists (ASCS): toward a new horizon: uniting cosmetic science with oriental wisdom. 2005.
Vañó-Galván S, Saceda-Corralo D, Blume-Peytavi U, Cucchía J, Dlova NC, Gavazzoni Dias MFR, et al. Frequency of the types of alopecia at twenty-two specialist hair clinics: A multicentre study. Skin Appendage Disord. 2019;5(5):309-15. DOI: https://doi.org/10.1159/000496708
Sakhiya J, Sakhiya D, Modi M, Gandhi S, Daruwala F. Prevalence, severity and associated factor of androgenetic alopecia in the dermatology outpatient clinic: A retrospective study. IP Indian J Clin Exp Dermatol. 2019;5(4):280-7. DOI: https://doi.org/10.18231/j.ijced.2019.060
Shankar DK, Chakravarthi M, Shilpakar R. Male androgenetic alopecia: population-based study in 1,005 subjects. Int J Trichol. 2009;1(2):131-3. DOI: https://doi.org/10.4103/0974-7753.58556
Adamowicz R, Załęcki P, Dukiel A, Nowicka D. Association between androgenetic alopecia and psychosocial disease burden: A cross-sectional survey among Polish men. Dermatol Res Pract. 2022;2022(1):1845044. DOI: https://doi.org/10.1155/2022/1845044
Sarkar R, Vartak S, Acharya S, Kursam NK, Mane A, Mehta S, et al. Comparative study to evaluate tolerability of topical 5% minoxidil novel formulation and alcohol-based conventional solutions in treatment of androgenetic alopecia in Indian men: Randomized double-blind study. Dermatol Ther (Heidelb). 2020;10(3):469-79. DOI: https://doi.org/10.1007/s13555-020-00374-y
Udare S, Baruah A, Mathur A, Dayananda TR, Jain K, Puhan MR, et al. Positioning of low alcohol or alcohol-free minoxidil formulation for the management of androgenetic alopecia: Indian perspective. Int J Trichol. 2023;15(1):13-17. DOI: https://doi.org/10.4103/ijt.ijt_54_22
Mirzaeei S, Barfar A, Mehrandish S, Ebrahimi A. A randomized, double-blind controlled clinical study to evaluate the efficacy and safety of minoxidil topical 2% nanosuspension with aqueous base in the treatment of androgenetic alopecia areata. J Rep Pharm Sci. 2021;10(2):279-86. DOI: https://doi.org/10.4103/jrptps.JRPTPS_25_21
Thuangtong R, Thanomkitti K, Suvanasuthi S. A comparative study between the efficacy and safety of 5% minoxidil solution and 5% minoxidil milky lotion in the treatment of male androgenic alopecia. J Med Assoc Thai. 2017;100(1):70-7.
Binjadeed H, Almudimeegh AM, Alomran SA, Alshathry AH. A case of contact allergic dermatitis to topical minoxidil. Cureus. 2021;13(1):e12510. DOI: https://doi.org/10.7759/cureus.12510
FriedmanES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: Etiology and treatment. J Am Acad Dermatol. 2002;46(2):309-12 DOI: https://doi.org/10.1067/mjd.2002.119104
Kaiser M, Abdin R, Gaumond SI, Issa NT, Jimenez JJ. Treatment of androgenetic alopecia: Current guidance and unmet needs. Clin Cosmet Investig Dermatol. 2023;16:1387-406. DOI: https://doi.org/10.2147/CCID.S385861
Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women, J Am Acad Dermatol. 2011;65(6):1126-34. DOI: https://doi.org/10.1016/j.jaad.2010.09.724
Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53. DOI: https://doi.org/10.1016/j.jaad.2003.06.014
Zac RI, da Costa A. Patient satisfaction and quality of life among adult women with androgenetic alopecia using 5% topical minoxidil. J Clin Aesthet Dermatol. 2021;14(5):26-30.
Rai PB, Khushwaha P, Jain N, Gupta S. Comparing the therapeutic efficacy of topical minoxidil and finasteride with topical minoxidil and oral finasteride in androgenetic alopecia: a randomized trial. Int J Res Dermatol. 2018;4(3):386-90. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20183163
Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759-81. DOI: https://doi.org/10.1111/jocd.14537
Karaca N, Akpolat ND. A comparative study between topical 5% minoxidil and topical “redensyl, capixyl, and procapil” combination in men with androgenetic alopecia. J Cosmetol Trichol. 2019;5(1):1-7.
Patwardhan NG, Bhide D, Shendkar S. Effectiveness and safety of alcohol-free minoxidil in the management of treatment-naive patients with androgenetic alopecia. Int J Res Dermatol. 2024;10(2):82-8. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20240394
Lalwala B, Das S, Murthy S, Saraswat A, Dhanalakshmi UR, Girdhar M, et al. Expert opinion on current and emerging treatment options in androgenetic alopecia and telogen effluvium: an Indian perspective Int J Res Dermatol. 2022;8(1):152-60. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20214926
Singh S, Patil A, Kianfar N, Waśkiel-Burnat A, Rudnicka L, Sinclair R, et al. Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit? Clin Exp Dermatol. 2022;47(11):1951-5. DOI: https://doi.org/10.1111/ced.15338
Shadi Z. Compliance to topical minoxidil and reasons for discontinuation among patients with androgenetic alopecia. Dermatol Ther (Heidelb). 2023;13(5):1157-69. DOI: https://doi.org/10.1007/s13555-023-00919-x
Sheikh S, Ahmad A, Ali SM. A new topical formulation of minoxidil and finasteride improves hair growth in men with androgenetic alopecia. J Clin Exp Dermatol Res. 2015;6(1):253.
Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men-short version. J Eur Acad Dermatol Venereol. 2018,32:11-22. DOI: https://doi.org/10.1111/jdv.14624
Dhariwala MY, Ravikumar P. An overview of herbal alternatives in androgenetic alopecia. J Cosm Dermatol. 2019;18(4):966-75. DOI: https://doi.org/10.1111/jocd.12930
Downloads
Published
How to Cite
Issue
Section
